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A full-term neonate suﬀered multifocal cerebral infarctions due to multiple large vessel thrombi. Thrombophilia and
cardiovascular assessments were negative, but due to the severity of the lesions and the concern for expansion of the thrombi
or future embolic events, treatment with low-molecular-weight heparin (LMWH) was initiated. No complications from treatment
were experienced. We present this severe case in order to highlight diﬃcult management decisions for newborns with multifocal
perinatal thromboembolic stroke and to stress the need for further practice guidelines and research in this area.
Copyright © 2009 Matthew A. Saxonhouse et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Perinatal stroke, occurring between 20 weeks’ gestation
through the 28th postnatal day [1–3], has a prevalence
ranging from 17.0 to 43.4 per 100000 live births [4–6]. The
majority (80%) of these events is ischemic in nature and
most abnormalities occur in the left hemisphere within the
distribution of the middle cerebral artery (MCA). Rarely,
multifocal cerebral infarctions can occur and these tend to
be embolic in origin [7, 8].
Despite the prevalence of perinatal stroke, no random-
ized clinical trials exist to address acute management or
prevention [1, 8, 9]. Current guidelines from the American
College of Chest Physicians (ACCP) suggest anticoagu-
lation or aspirin therapy only for neonates with a ﬁrst
perinatal stroke with a documented ongoing cardioembolic
source (Grade IB) or recurrent arterial ischemic stroke
(AIS; Grade 2C) [9]. However, recent recommendations
from the American Heart Association (AHA) suggest that
anticoagulation may be selected in neonates with mul-
tiple cerebral emboli (Class IIb, Level of Evidence C)
[1].
We present a neonate who suﬀered multifocal cerebral
infarctions due to thrombosis of ﬁve vessels. No evidence
suggested cardiac disease or a prothrombotic disorder. Due
to the severity, size, and locations of the thrombi, plus
the multifocal presentation of the cerebral infarctions, we
decided to anticoagulate the patient with low-molecular-
weight heparin (LMWH) in an attempt to decrease the risk
of extension of the thrombi and/or secondary emboli. This
case of multifocal thromboembolic perinatal stroke repre-
sents the most severe end of the spectrum and highlights
the diﬃculties inherent in management of these types of
patients.2 Advances in Hematology
2.CaseReport
A 40-week, 2884g, female infant was delivered via cesarean
section to a 41-year-old primigravida after arrest of descent
and failed vacuum extraction. Complications of the preg-
nancy included a history of infertility, gestational diabetes
(glyburide controlled), prolonged rupture of membranes,
and chorioamnionitis. Apgar scores were 1, 7, and 8. Umbil-
ical artery and venous pH were 6.94 and 7.06, respectively.
Initial blood testing was nonspeciﬁc. Physical examination
was signiﬁcant for a large left caput succedaneum with a soft
andﬂatanteriorfontanel.Neurologicalexaminationdemon-
strated mild hypotonia. At approximately 36 hours of age,
the patient had seizure activity consisting of eye ﬂuttering,
bilateral clonic movements of the upper extremities, and
tongue thrusting. Two separate events occurred, each lasting
less than three minutes.
Repeat blood testing revealed a normal glucose level, no
signiﬁcant electrolyte abnormalities, a white blood count of
9.8 ×103/mm3, and hematocrit of 46.8%. The platelet count
had decreased from 155 (initial) to 119 × 103/mm3 with
subsequent drop to 109 × 103/mm3 twenty four hours later.
Cerebrospinal ﬂuid evaluation revealed (traumatic lumbar
puncture) 115000/mm3 red blood cells, 50/mm3 white
blood cells with 87% polys and 12% lymphs. The patient was
given a loading dose of phenobarbital, and ampicillin and
gentamicin had been started shortly after birth.
Magnetic resonance imaging (MRI) of the brain
(Figure 1) demonstrated bilateral multifocal regions of
increased signal on diﬀusion-weighted imaging in the left
pons, left occipital lobe, left thalamus, left and right frontal
lobes, and left and right frontoparietal regions. No evidence
indicated hemorrhage, and all of the lesions were dark
on apparent diﬀusion coeﬃcient of water (ADC) mapping
indicating that they were acute in nature (within 1 week). A
transthoracic echocardiogram demonstrated normal cardiac
anatomy with no intracardiac thrombus or vegetation. Mag-
netic resonance angiography (MRA) of the head and neck
without contrast (Figure 2) demonstrated occlusion of the
right internal carotid artery (ICA) at its origin without distal
reconstitution. Collateral ﬂow directed blood through the
anterior communicating artery to the right anterior cerebral
artery (ACA) and right middle cerebral artery (MCA). The
vertebral arteries were diminutive and the basilar artery was
occluded. The posterior communicating arteries and PCAs
were not visualized. With this extent of vessel occlusion,
even more widespread brain infarction might be expected.
However, the complex distribution of the infarcts demon-
stratedondiﬀusion-weighted imagescanbeexplained bythe
relative robustness of the patient’s leptomeningeal collateral
vessels. EEG evaluation demonstrated left parieto-occipital
spike wave discharges with associated slowing, excessive
subtransients for age, and mild slowing and suppression of
background activity.
Bacterial and viral studies were negative. Placental
pathology demonstrated a third trimester placenta with
acute necrotizing chorioamnionitis and a three-vessel cord
with acute funisitis (inﬂammation of the umbilical cord).




Figure 1: (a)–(c): Axial diﬀusion-weighted images, b = 1000,
demonstrate multiple areas of high signal in bilateral frontal and
parietal lobes, left occipital lobe, left thalamus, and left pons.
four (Table 1) failed to identify any inherited or acquired
prothrombotic risk factors. However, other than negative
DNA mutation analysis, deﬁnitive protein abnormalities
c o u l dn o tb er u l e do u tu n t i lr e p e a te v a l u a t i o np e r f o r m e da t
3–6monthoflife[10].Statemetabolicscreeningthroughthe
State of Florida was negative.
Prior to the results of the thrombophilia evaluation, we
decided to anticoagulate the patient with LMWH. We basedAdvances in Hematology 3
Table 1: Thrombophilia Evaluation Performed [10, 11].
Test Performed Test Performed
PT ∗1a n d∗2 Anti-B2 glycoprotein IgG 1 and 2
INR 1 and 2 Anti-B2 glycoprotein IgM 1 and 2
aPTT 1 and 2 Anti-phosphatidylserine IgG 1 and 2
Fibrinogen 1 and 2 Anti-phosphatidylserine IgM 1 and 2
Factor V Leiden 1 Heparin cofactor 2 1 and 2
Prothrombin 20210 1 Homocysteine 1 and 2
MTHFR 1 Lipoprotein (A) 1 and 2
Protein C activity 1 and 2 Antithrombin 1 and 2
Protein S activity 1 and 2 Factor VIII activity 2
Anticardiolipin IgG 1 and 2 Lupus anticoagulant 2
Anticardiolipin IgM 1 and 2 Factor XII activity 2
Plasminogen 2
PT: prothrombin time; aPTT: activated partial thromboplastin time; INR: international normalized ratio; MTHFR: methylenetetrahydrofolate reductase.
∗1 Test performed at day of life no. 4; ∗2 Test performed at four months of age.
Figure 2: 3D maximum-intensity projection (MIP) image from
a 3D time of ﬂight MRA demonstrates occlusion of the right
internal carotid artery at its origin (arrow). The vertebral arteries
are diminutive (arrowheads) and the basilar artery is not visualized.
this decision on the occlusion of multiple large blood vessels
with evidence of multifocal cerebral infarctions, a pattern
indicative of an embolic process. Our rationale for choosing
LMWH was to decrease the risk of clot extension, which
was suggested by the progressive thrombocytopenia. LMWH
was initiated, using a therapeutic antifactor Xa level of 0.5–
1.0IU/mL.
The patient had no further seizure activity, and gradually
improvedduringheradmission.Theplateletcountincreased
after starting therapy to 156 × 103/mm3 and then 253 ×
103/mm3,a t4 8h o u r sa n d9 6h o u r s ,r e s p e c t i v e l y .S h ew a s
discharged home on day of life 13 from the neonatal
intensive care unit taking full oral feedings, and her family
was instructed to continue phenobarbital and LMWH with
scheduled follow-up.
MRI evaluation at four months of age demonstrated
bilateral encephalomalacia in areas of prior infarction
with no evidence of current or prior hemorrhage. Mild
encephalomalacia was also seen in the right PCA territory,
which was not ischemic on the initial MRI. This likely
reﬂected an additional infarct which most likely occurred
during or soon after the initial scan, possibly before the
initiation of LMWH. MRA evaluation (Figure 3) revealed
resolution of the right ICA thrombus with overall decreased
caliber of the vessel compared to the left, and residual
irregularity and narrowing at the superior cervical segment.
The intracranial vessels were all patent, although the right
PCA was diminutive. Repeat thrombophilia assessment at
four months of life was negative (Table 1).
We discontinued LMWH treatment after obtaining the
results of the repeat MRI, MRA, and thrombophilia evalua-
tions. Neurological evaluation at 4.5 months of age demon-
strated asymmetric tracking and blinking to confrontation
which was worse on the left, mildly increased ﬂexor tone of
the left upper extremity, normal lower extremity tone and
reﬂexes bilaterally, and age appropriate milestones for gross
motor, ﬁne motor, and social interaction. No seizure activity
has been observed or suggested on EEG evaluation, and
phenobarbital has been weaned. Neuro-ophthalmological
examination at 6 months of age demonstrated normal visual
acuity for age and normal blinking to confrontation. The
patient continues to thrive and develop at home.
3. Discussion
Multifocal cerebral infarction is a rare type of perinatal
stroke that tends to be embolic in origin [8]. Despite
the multiple risk factors ascribed to perinatal stroke, little
evidence exists to inform management of these infants after
initial stabilization [1, 9]. Previous studies of perinatal stroke
havebeenlimitedduetosmallsamplesizeorlackofadequate
control groups [6, 8].
CurrentACCPguidelinessuggestthatonlyneonateswith
proven cardioembolic arterial ischemic stroke or those with4 Advances in Hematology
(a)
(b)
Figure 3: 3D MIP images from a noncontrast 2D time of ﬂight
MRA demonstrate restoration of ﬂow in the right internal carotid
artery and posterior circulation. Residual occlusion of the distal
right PCA persists (arrow).
recurrent arterial ischemic stroke should receive treatment
with anticoagulation or aspirin therapy [9]. Recommen-
dations from a special writing group of the AHA stroke
council and the council on cardiovascular disease in the
young [1] suggest that anticoagulation may be considered
in neonates with multiple cerebral emboli. Both of these
recommendations are based on expert opinion and case
series/reports. However, they leave the clinician with diﬃcult
treatment decisions to make when faced with a neonate with
severe multifocal perinatal thromboembolic stroke (such as
our case report).
Recent research has demonstrated increasing evidence
that LMWH may play a pivotal role in perinatal stroke [12].
Studies in pediatric patients have shown eﬃcacy and safety
of LMWH similar to that observed in adults, and they have
demonstrated that LMWH prevents progression of stroke,
development of new symptomatic thrombi, and extensions
of existing thrombi [12–14]. Punzalan et al. present two
children with internal carotid artery thrombi who had either
complete or partial resolution of thrombi while being treated
with LMWH [13]. One of the largest neonatal studies involv-
ing LMWH demonstrated that with careful monitoring and
laboratory evidence of therapeutic LMWH eﬀect, complete
or partial resolution of thromboembolism was achieved in
the majority of cases [15]. Signiﬁcant bleeding occurred in
four of the 62 infants, but none of the events resulted in
severe sequelae or death. Other studies and case reports have
not only demonstrated similar eﬃcacy, but also decreased
clot extension and prevention of embolic phenomenon [16].
Onelimitationwithapplyingthesereportstoperinatalstroke
is that only four patients in these studies had clots in the
central nervous system [15]. Although LMWH does appear
to be a safe medication for treatment and prophylaxis of
neonates with perinatal stroke, individual judgment (for
now) should be applied to speciﬁc cases.
This case is characteristic of the severe end of the
spectrum of perinatal stroke and emphasizes the diﬃcult
acute management decisions regarding such neonates. The
comprehensive ACCP guidelines provide recommendations
that facilitate the standardized use of antithrombotic and
thrombolytic therapy in neonates and children. We appre-
ciate that extreme cases, such as the one presented, are
not routinely encompassed by such guidelines, and in
these situations optimal treatment may fall outside the
recommendations provided. Other sources (such as those
of the AHA) can be referred to in order to provide some
guidance but the physician may ultimately have to make a
balanced decision.
We decided to treat the neonate described above with
LMWH based on the severity of the thrombus in the right
internal carotid artery and the multifocal nature of the
arterial ischemic stroke. Although the probable source of
the initial thrombus was the placenta, we believed that
there was a high risk for extension of the internal carotid
thrombus and/or furtherembolic complications. We felt that
the potential risk associated with bleeding was signiﬁcantly
less than the devastating ramiﬁcations of further central
nervoussysteminsult.Ourpatientsuﬀerednocomplications
from the treatment and had resolution of the thrombi,
thus supporting the safety and eﬃcacy of LMHW in
neonates.
We cannot prove deﬁnitively that LMWH resulted in
clot resolution without a similar control patient and a
timeline involving serial imaging studies. Serial MRA/MRI
was not performed due to the extreme cost and the
potential morbidity associated with repeated sedation. The
patient’s thrombocytopenia and clinical condition improved
after initiation of LMWH, suggesting that LMWH halted
clot extension. Moreover, the follow-up MRI/MRA after
four months of LMWH treatment demonstrated almost
complete recanalization of the cerebral vessels. This MRI did
demonstrate encephalomalacia in the right PCA territory
which was not predicted from the original infarct pattern.
However, based on consistent clinical improvement, we
strongly feel that this infarct occurred in close proximity to
the initial MRI, most likely before the initiation of LMWH.
In addition, it suggests that LMWH may have prevented
further infarcts. Therefore, we feel that this case supports the
recommendations provided by the AHA for LMWH treat-
ment in complex cases of multiple cerebral emboli. While
we recognize that one case study does not represent strongAdvances in Hematology 5
evidence, we propose that when the ACCP guidelines are
again updated, the authors consider review and inclusion of
a subset of patients with severe multifocal noncardioembolic
stroke who may beneﬁt from anticoagulation. This case also
highlights the need for controlled clinical trials to address
the management of the broad spectrum of perinatal stroke
[2].
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